Arena's Lorcaserin Reaches FDA, But Without REMS Proposal

Arena Pharmaceuticals filed the NDA for its obesity drug lorcaserin Dec. 22, crossing the top item off the firm's news flow list and refocusing attention on the drug's partnering potential in a shifting regulatory and competitive landscape

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet